Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price Target
Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics (NASDAQ:HRTX) in a research report sent to investors on Friday, January 5th. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages also recently commented on HRTX. ValuEngine upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Sunday, December 31st. Leerink Swann began coverage on Heron Therapeutics in a research report on Tuesday, January 2nd. They set an outperform rating and a $22.00 price objective for the company. BidaskClub upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, December 20th. Zacks Investment Research upgraded Heron Therapeutics from a sell rating to a hold rating in a research report on Wednesday, November 8th. Finally, Noble Financial restated a buy rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Heron Therapeutics currently has an average rating of Buy and a consensus price target of $28.82.
Heron Therapeutics (HRTX) traded down $0.40 on Friday, reaching $23.90. The company’s stock had a trading volume of 947,181 shares, compared to its average volume of 1,110,000. The firm has a market capitalization of $1,300.00, a P/E ratio of -6.31 and a beta of 2.12. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 12-month low of $12.25 and a 12-month high of $24.80.
In other news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 19.93% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. Janus Henderson Group PLC acquired a new position in shares of Heron Therapeutics in the second quarter worth $78,134,000. Perceptive Advisors LLC acquired a new position in shares of Heron Therapeutics in the third quarter worth $5,329,000. Vanguard Group Inc. increased its position in Heron Therapeutics by 11.8% during the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after buying an additional 221,362 shares during the last quarter. Rubric Capital Management LP increased its position in Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after buying an additional 200,000 shares during the last quarter. Finally, Chartwell Investment Partners LLC acquired a new position in Heron Therapeutics during the third quarter worth $2,340,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.